Milestone Scientific's Voro Urologic Scaffold Shows Promise in Prostate Cancer Surgery Trials
- Milestone Scientific is advancing patient care with the innovative Voro® Urologic Scaffold for prostate cancer surgery.
- The ARID II clinical trial has reached halfway enrollment, assessing the safety and effectiveness of the Voro scaffold.
- Interim results show promising continence recovery rates, validating the Voro scaffold's efficacy in urologic surgery.
Milestone Scientific Advances with Innovative Urologic Scaffold Technology
Milestone Scientific, a leader in the medical device industry, focuses on advancing patient care through innovative technologies. The company has made significant progress with its Voro® Urologic Scaffold, which is designed to improve outcomes for patients undergoing prostate cancer surgery. Recently, Milestone announced that the ARID II pivotal clinical trial has reached its halfway enrollment milestone, signaling strong momentum in this multicenter, randomized study aimed at assessing the safety and effectiveness of the Voro Urologic Scaffold in men receiving robotic-assisted radical prostatectomy. This development underscores Milestone’s commitment to enhancing surgical outcomes through cutting-edge medical technology.
The Voro Urologic Scaffold has garnered attention for its promising results in previous studies, such as the ARID Study, which highlighted a favorable safety profile and significant continence recovery rates among patients. Dr. Lee Richstone from Northwell Urology expressed optimism regarding the scaffold's potential to improve recovery outcomes, as interim results indicated that over half of the patients achieved continence by six weeks and over 70 percent by six months. This positive trajectory not only validates the efficacy of the Voro scaffold but also positions Milestone Scientific at the forefront of innovation in urologic surgery.
Milestone’s commitment to enhancing patient outcomes is further exemplified by their focus on generating robust clinical evidence. The publication of interim results in the World Journal of Urology is pivotal for advancing the Voro scaffold’s clinical acceptance and reimbursement potential. Jeffrey Dann, MD, emphasized that this peer-reviewed evidence is crucial for transitioning the scaffold’s Category III CPT code to Category I status, which would facilitate broader access and utilization in clinical practice. As Milestone Scientific continues to innovate in the medical device space, the Voro Urologic Scaffold stands as a testament to the company’s dedication to improving the quality of care for patients undergoing prostate cancer surgery.
In addition to its advancements in prostate cancer treatment, Milestone Scientific remains focused on broadening its impact within the healthcare landscape. The ongoing clinical trials and positive feedback from the medical community highlight the significance of evidence-based innovations in medical devices. With a strategic emphasis on patient outcomes and clinical validation, Milestone is poised to redefine standards in urologic healthcare.
Milestone Scientific also aims to strengthen its market position through collaborations and partnerships, enhancing its ability to deliver effective, innovative solutions. As the company progresses in its clinical trials and focuses on expanding its portfolio, it reinforces its commitment to providing high-quality, evidence-based medical solutions that cater to the evolving needs of patients and healthcare providers alike.